China Tightens Drug-Precursor Export Controls as Fentanyl Returns to the U.S.–China Negotiating Table

China’s Ministry of Commerce, together with four other government agencies, announced that two additional precursor chemicals would require export permits when shipped to the United States, Mexico or Canada. The newly listed substances are piperidone-related compounds associated with the fentanyl precursor supply chain. The controls took effect immediately and cover the chemicals as well as their possible salts. Importantly, the measure is targeted rather than global: China requires licensing for these 18 chemicals when exported to the three North American countries, while a separate group of 41 controlled chemicals remains subject to licensing for shipments to Myanmar, Laos and Afghanistan. This means the measure should be understood primarily as a tighter compliance regime for sensitive chemical trade rather than a broad restriction on China’s pharmaceutical or chemical exports.

The latest action builds on several rounds of regulation that have tracked the development of U.S.–China negotiations. In November 2025, Beijing placed 13 fentanyl-related precursors under special export controls for the United States, Canada and Mexico. Three more were added in May 2026, taking the total to 16 before this week’s expansion to 18. Chinese authorities say customs agencies have also strengthened risk assessments and supervision of sensitive chemical exports, while Chinese and American law-enforcement agencies have continued exchanging information and cooperating on individual narcotics investigations. The sequence suggests that precursor control has become one of the few areas where Washington and Beijing have been able to translate high-level political negotiations into relatively concrete regulatory measures.

The issue also has a significant trade-policy dimension. Early in Donald Trump’s second term, Washington imposed additional tariffs on Chinese products under emergency economic powers, arguing that Beijing was not doing enough to stop chemicals used in illicit fentanyl production from reaching North America. Following negotiations with Xi in late 2025, the United States cut the fentanyl-related tariff rate from 20% to 10% after China committed to stronger controls. That tariff structure was subsequently invalidated in February 2026 when the U.S. Supreme Court ruled that the International Emergency Economic Powers Act did not give the president authority to impose tariffs. The ruling did not eliminate other U.S. tariffs on China, however, and fentanyl remains part of the wider negotiating agenda alongside rare earths, technology restrictions, agricultural trade and artificial intelligence.

Beijing reinforced its regulatory message on September 23 by issuing new guidelines governing criminal cases involving fentanyl-related substances. The rules clarify how Chinese courts, prosecutors and police should handle crimes involving medicinal and non-medical fentanyl-related substances and establish clearer standards for prosecution and sentencing. Taken together with the expanded export licensing requirements, the measures allow Beijing to demonstrate action on both the outbound chemical supply chain and domestic criminal enforcement immediately before the Trump-Xi meeting. For businesses, the direct effect is higher compliance and licensing requirements for a relatively narrow group of chemical exporters. At the macro level, however, the significance is larger: progress on fentanyl gives both governments a measurable area of cooperation that could help manage broader economic tensions, even though it does not resolve the much larger disputes over trade, technology and strategic competition.